Cipla Share Price Target 2025, 2026, 2028, 2030, 2035

Cipla Share is a bullish trend in the share market. During share ups and downs, you should know all about share details before investing. In this blog, we are going to discuss Cipla Share Price Target 2025, 2026, 2028, 2030, and 2035. We will try to analyze the share base in the company’s overall performance.

We also look after the company’s profit growth in the last 5 years, the last 5 years’ sales growth, and the last 5 years’ ROE percentage. Similarly, we also compare the share growth, the share price return amount of the share has increased or decreased over the last 5 years. We also take advice from experts about when we should invest in the share, which may be helpful for you. Let’s have a look at the Cipla Share Price Target from 2025 to 2035.

Overview Of Cipla Limited

Cipla Limited is an Indian multinational pharmaceutical company which was established in the year 1935. The company has 47 manufacturing locations across the world and sells its products in 86 different countries. The company primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, diabetes, paediatric, and various other medical conditions. The headquarters of the company is situated in Mumbai.

Fundamental Analysis Of Cipla Limited

Company Name	Cipla Limited
Market Cap	₹1,19,042 Crore
P/B	3.87
Face Value	₹2
Book Value	₹379.78
52 Week High	₹1,725
52 Week Low	₹1,317.60
ROE	14.67%
DIV. YIELD	0.90%
P/E	26.10

Last Few Years Performance Of Cipla Limited

Profit Growth

The profit growth percentage of the company in the last 5 years is described below.

• In the last 5 years 16.67%
• In the last 3 years 18.79%
• In the last 1 year 62.89%

The Net Profit amount of the company was ₹2,578.59 Crore in March 2023, which increased to ₹4,098 Crore in March 2024. The Operating Profit amount of the country was ₹3,347.98 Crore in March 2023, which increased to ₹4,678.89 Crore in March 2024.

Sales Growth

The sales growth percentage of the company in the last 5 years is described below.

• In the last 5 years 6.05%
• In the last 3 years 13.89%
• In the last 1 year 15.98%

The Net Sales amount of the company was ₹4,780 Crore in September 2023, which increased to ₹4,977 Crore in December 2024.

ROE Percentage

The ROE percentage growth of the company in the last 5 years is described below.

• In the last 5 years 12.98%
• In the last 3 years 12.66%
• In the last 1 year 14.76%

ROCE Percentage

The ROCE percentage growth of the company in the last 5 years is described below, which also increased rapidly.

• In the last 5 years 16.89%
• In the last 3 years 17.01%
• In the last 1 year 19.01%

Total Expenditure Amount

The Total Expenditure amount of the company was ₹11,034.78 Crore in March 2023, which increased to ₹12,235.90 Crore in March 2024.

The Net Cash Flow Amount

The Net Cash Flow amount of the company was -₹1,47.97 Crore in March 2023, which increased to ₹136.89 Crore in March 2024.

Total Assets Amount

The company’s Total Assets were ₹27,467.09 Crore in March 2023, which increased to ₹31,567.98 Crore in March 2024.

Also Read – Zomato Share Price Target

Cipla Share Price Target 2025

Cipla Share Price Target 2025 forecast may vary from ₹1,428.70 to ₹1,599.60.

Influencing Key Factor Of Cipla Share Price Target 2025

• Partnership With Big Pharmaceutical Companies
• Cipla Limited is the second largest in the chronic branded prescription business. It has a strong market share, with an increasing chronic share from 56% to 59%. The scale-up in the branded licensing business is driven by well-entrenched partnerships with global pharma companies. With the continuous rigor of making big brands bigger, more than 20 brands have crossed the 100 crores mark in the Indian Pharma Market. The company also scales up in the branded In-licensing business driven by well-entrenched partnerships with global pharma companies.
• Business In South Africa
• Cipla Limited continues to be the 3rd largest pharmaceutical corporation in the South African private market. Cipla’s private market business continues to outperform the market with a strong growth of 4.8% approximately. In the South African market, 30 new brands were launched in the market across multiple therapies during the year. In the year 2022-23, the private market further improved its share to 78% in the South African Market.

Month	Cipla Share Price Target 2025 (1st Price Target)	Cipla Share Price Target 2025 (2nd Price Target)
March	₹1,428.70	₹1,484.32
April	₹1,485.67	₹1,527.09
May	₹1,520.58	₹1,567.45
June	₹1,550.32	₹1,569.80
July	₹1,560.77	₹1,579,54
August	₹1,578.40	₹1,597.69
September	₹1,595.57	₹1,645.81
October	₹1,639.07	₹1,670.34
November	₹1,645.78	₹1,689.76
December	₹1,534.87	₹1,599.60

Cipla Share Price Target 2026

Cipla Share Price Target 2026 forecast may vary from ₹1,622.98 to ₹1,793.90.

Influencing Key Factor Of Cipla Share Price Target 2026

• Business In International Markets
• 13% revenue of the company’s business came from International Markets. Cipla is the fastest-growing pharma company in Sri Lanka, amongst the top 10, and also featured in the top 10 list of the Nepalese pharma market for the first time. Strong respiratory fillings done in European markets to strengthen the future pipeline. Continued focus on growth through organic launches and biosimilar footprint.
• Business In North America
• Cipla Limited is one of the top 100 players by prescription in the US market. Business crosses USD 730 million and revenue for the first time, and highest ever quarterly sales of USD 204 million led by differentiated portfolio. 55% of the company’s commercial portfolio ranks top 3 in market share. Cipla’s private market business continues to outperform the market with a strong growth of 4.9%.
• Revenue From Operations
• The revenue from operations increased rapidly. In the financial year 2021-22, the company’s revenue amount from operations was ₹21,765 Crore in the year 2021-22, which increased to ₹22,756 Crore in the year 2022-23.

Month	Cipla Share Price Target 2026 (1st Price Target)	Cipla Share Price Target 2026 (2nd Price Target)
January	₹1,622.98	₹1,640.76
February	₹1,635.67	₹1,648.89
March	₹1,642.75	₹1,666.95
April	₹1,663.90	₹1,687.89
May	₹1,688.09	₹1,789.78
June	₹1,788.56	₹1,798.34
July	₹1,810.67	₹1,865.09
August	₹1,834.56	₹1,889.60
September	₹1,885.77	₹1,950.08
October	₹1,949.65	₹1,989.60
November	₹1,988.09	₹2,067.67
December	₹1,701.78	₹1,793.90

Cipla Share Price Target 2028

Cipla Share Price Target 2028 forecast may vary from ₹2,034.90 to ₹2,197.70.

Influencing Key Factor Of Cipla Share Price Target 2028

• Manufactured Capital
• Cipla Limited diversified product portfolio of 1,500 products, more than 50 dosage forms, and 65 therapeutic categories. In the financial year 2024, the company successfully launched 101 new products across geographies. 298 patents as of March 2024. 10 clinical trials have been completed. 2,204 cumulative DMFs and 277 cumulative ANDAs and NDAs filed.
• Manufacturing Branches
• Cipla Limited has 34 manufacturing units in 8 locations across India and a presence in over 80 countries. Exports accounted for 48% ₹4,948 Crore (equivalent to ₹84 billion) of its revenue for the year 2013-14. Cipla Limited spent ₹517 Crore (5.4% of their revenue) in the year 2013-14 fiscal year on R&D activities. The primary focus areas for R&D were development of new formulations, drug delivery systems, and APIs.
• Enter Into Digital Therapeutics
• In the year 2019, Cipla entered digital therapeutics by partnering with Wealthy Therapeutics in India and Brandmed in South Africa.

Month	Cipla Share Price Target 2028 (1st Price Target)	Cipla Share Price Target 2028 (2nd Price Target)
January	₹2,034.90	₹2,079.45
February	₹2,067.24	₹2,097.93
March	₹2,095.31	₹2,156.75
April	₹2,149.10	₹2,178.56
May	₹2,170.32	₹2,199.75
June	₹2,198.15	₹2,256.54
July	₹2,254.20	₹2,298.07
August	₹2,289.67	₹2,367.36
September	₹2,360.54	₹2,456.70
October	₹2,401.35	₹2,438.57
November	₹2,199.83	₹2,267.08
December	₹2,105.67	₹2,197.70

Also Read – Voltas Share Price Target

Cipla Share Price Target 2030

Cipla Share Price Target 2030 forecast may vary from ₹2,436.90 to ₹2,589.32.

Influencing Key Factor Of Cipla Share Price Target 2030

• Entered Into Generic Treatment
• Cipla Limited produced a low-cost drug to treat HIV and expanded operations into several developing countries including African nations, where most HIV and poor patients existed at one time. However, the changes made led to criticism of both India’s patent laws and Cipla.
• Medical Tourism
• Cipla Limited provides its valuable drugs in different countries through medical tourism. The company provides its medicines all over the country through medical tourism.
• Leadership Strategy
• Cipla Limited is developing new drug formulations for existing and newer drug substances, improving processes for existing API and formulation products. The company has also tied up with independent research teams to develop new products.

Month	Cipla Share Price Target 2030 (1st Price Target)	Cipla Share Price Target 2030 (2nd Price Target)
January	₹2,436.90	₹2,498.76
February	₹2,401.52	₹2,478.67
March	₹2,469.44	₹2,510.30
April	₹2,508.49	₹2,545.72
May	₹2,540.75	₹2,589.62
June	₹2,585.32	₹2,624.28
July	₹2,609.50	₹2,681.75
August	₹2,679.31	₹2,699.67
September	₹2,670.66	₹2,698.50
October	₹2,689.45	₹2,735.78
November	₹2,510.56	₹2,567.08
December	₹2,505.98	₹2,589.32

Cipla Share Price Target 2035

Cipla Share Price Target 2025 forecast may vary from ₹3,214.45 to ₹3,378.60.

Influencing Key Factor Of Cipla Share Price Target 2035

• Strong Marketing And Distribution Network
• Cipla Limited has a strong marketing team, through the team, the company is able to capture the market position in all of India and outside India as well. The company also has a good distribution network through which the company is able to distribute its products at the right place at the right time.
• Grow In Emerging Markets
• Cipla Limited should look forward to growing in emerging markets, especially places where medical infrastructure is improving, and hence pharmaceutical is also expected to grow.
• Covid-19 Drug
• Cipla has launched with Gilead Sciences for potential COVID-19 treatment drug remdesivir, an injectable drug used in treating COVID-19 patients with severe conditions, in India.

Year	Cipla Share Price Target 2035
1st Price Target	₹3,214.45
2nd Price Target	₹3,378.60

Peers Company Of Cipla Limited

Company Name	Market Cap (Crore)
Aarey Drugs	₹103.47
Aarti Drugs	₹3,118.27
Abbott India	₹62,918.89
Ajanta Pharma	₹31,743.98
Alembic Pharma	₹16,278.90

Discussion About Share Holding Pattern Of Cipla Limited

Cipla Limited mainly has four types of shareholding patterns such as promoter holding, public holding, DII, and FII. Depending on the shareholding pattern, we can majorly influence the company’s growth.

Investor Type	Percentage
Promoter Holding (Owned by the company’s promoter)	29.20%
Public Holding (Held by the public)	16.60%
FII (Invest by Foreign Institutional Investor)	26.50%
DII (Invest money by Domestic Institutional Investor)	27.70%

The Last Few Years’ Share Price Updation Of Cipla Limited Share

Cipla Limited Share always gives good returns to investors, which is described in the portion below.

• In the last 6 months, share growth was -199.35 (-12.01%).
• The last 1 month’s share growth was -14.60 (-0.99%).
• The last 1 year’s share growth was -28.00 (-1.88%).
• The last 5 years’ share growth was +1,034.50 (243.10%).
• The maximum share growth was +1,436.58 (6,120.92%).

• Cipla’s Share price return percentage was 0.17% in the last 1 month.
• The last 3 months’ share growth was 1.05%.
• The last 1 year’s share growth was -2.32%.
• The last 3 years’ share growth was 39.41%.
• The last 5 years’ share growth was 243.54%.

Cipla Share always gives good returns to the investor. If anyone wants to invest in the share, it will be profitable on a long-term basis.

What Is The Expert Advise About The Investment In Cipla Share

Positive Sides

• In the last 3 years, the company had a good profit growth, which was 18.79%.
• The company has a healthy interest cover ratio which is 245.36.
• The company is virtually debt-free.
• The FII investor percentage of the company is also increasing to 26.50%.
• The company has a healthy ROE percentage which is 12.66%.

Negative Sides

• The last 3 years revenue growth was not good, which was 13.65%.
• The promoter holding capacity of the company should be improved from 29.20%.

Risk Factors Of Cipla Limited Share

• Cipla Limited has a presence in over 170 countries, but India is a major revenue generator.
• India has proposed a new pricing policy under the drug price control, which can bring down the industry.
• Indian companies need USFDA regulatory approvals for facilities and observations, as it affects their sales.
• Due to fluctuations in exchange rates, the international business may also be affected.
• Intense competition in the Indian generics industry comes from major competitors such as Lupin, Sun Pharma, etc. This affects Cipla’s growth potential and limits its market share.

Also Read – Asian Paints Share Price Target

FAQ

Conclusion

This website is written to help the investor gain some basic knowledge about the market strategy of Cipla Share. For making this blog, we consulted experts and researched the company. It is expected that the Cipla Share Price Target will be a good choice to invest in on a long-term basis. The demand for the pharmaceutical sector in India and outside of the country always increases as a result of the company and the share may increase rapidly.

We try to give an in-depth idea about the share. If you think it is helpful to you you can share it. If you have any questions please let us know through the comment box we will try to reply to your questions and solve your problem. Thanks for visiting this website and thanks for being with us.

Disclaimer – We are not SEBI-registered advisors. A financial market is always risky to anyone. This website is only for training and educational purposes. So before investing, we are requested to discuss certified expertise. We will not be responsible for anyone’s profit or loss.